## Abstract Ataxia telangiectasia mutated protein (ATM) is a member of the phosphatidylinositol‐3 kinase (PI3K) family, which has a role in the cellular response to DNA double‐strand breaks (DSBs). In the present study, we evaluated the role of ATM in cell‐cycle control in dopaminergic rat neurobla
Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control
✍ Scribed by Thomas Oelgeschläger
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 184 KB
- Volume
- 190
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The carboxyl‐terminal domain (CTD) of the largest subunit of mammalian RNA polymerase II (RNAP II) consists of 52 repeats of a consensus heptapeptide and is subject to phosphorylation and dephosphorylation events during each round of transcription. RNAP II activity is regulated during the cell cycle and cell cycle‐dependend changes in RNAP II activity correlate well with CTD phosphorylation. In addition, global changes in the CTD phosphorylation status are observed in response to mitogenic or cytostatic signals such as growth factors, mitogens and DNA‐damaging agents. Several CTD kinases are members of the cyclin‐dependent kinase (CDK) superfamily and associate with transcription initiation complexes. Other CTD kinases implicated in cell cycle regulation include the mitogen‐activated protein kinases ERK‐1/2 and the c‐Abl tyrosine kinase. These observations suggest that reversible RNAP II CTD phosphorylation may play a key role in linking cell cycle regulatory events to coordinated changes in transcription. J. Cell. Physiol. 190: 160–169, 2002. © 2002 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract tsAF8 cells are a temperature‐sensitive mutant of BHK cells that arrest at the nonpermissive temperature in the G~1~ phase of the cell cycle. The activity of solubilized RNA polymerase II and its ability to bind [^3^H]‐γ‐amanitin decrease in tsAF8 cells at 40.6°, with a half‐life of ∼ 1
## Abstract Fibroblast growth factor (FGF‐2) and its endogenous antisense RNA FGF antisense (FGF‐AS) have been implicated in cancer progression and correlated with clinical outcomes of cancer patients. We previously reported that elevated FGF‐AS expression is associated with reduced tumor recurrenc